Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong
We assessed Cordyceps sinensis mycelium culture extract (Cs4) for alleviating long COVID symptoms. In this randomized trial 110 participants were assigned to receive Cs4 (55 participants) or were waitlisted (55 participants) for 12 weeks. The primary outcome was the change in long COVID symptom se...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2025-01-01
|
| Series: | Acta Materia Medica |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839648525206421504 |
|---|---|
| author | Yuanyuan Chen Guang Chen Cheng Zhang Guoyi Tang Yautuen Chan Ning Wang Yibin Feng |
| author_facet | Yuanyuan Chen Guang Chen Cheng Zhang Guoyi Tang Yautuen Chan Ning Wang Yibin Feng |
| author_sort | Yuanyuan Chen |
| collection | DOAJ |
| description | We assessed Cordyceps sinensis mycelium culture extract (Cs4) for alleviating long COVID symptoms. In this randomized trial 110 participants were assigned to receive Cs4 (55 participants) or were waitlisted (55 participants) for 12 weeks. The primary outcome was the change in long COVID symptom severity at 12 weeks, as measured by the modified COVID-19 Yorkshire Rehabilitation Scale. The secondary outcomes included changes in the Brief Fatigue Inventory Form, Insomnia Severity Index, Hospital Anxiety and Depression Scale, St. George’s Respiratory Questionnaire, and the Short Form 12 health survey at 12 weeks. Participants receiving Cs4 showed improvement in long COVID symptoms compared to the waitlist control group (MD, −10.1; 95% CI, −14.1 to −6.1; P < 0.001) at 12 weeks. Cs4 recipients also experienced improvement in fatigue (MD, −8.1; 95% CI, −14.2 to −2.0; P = 0.011), insomnia (MD, −2.9; 95% CI, −4.6 to −1.2; P = 0.001), and respiratory symptoms (MD, −6.3; 95% CI, −11.4 to −1.2; P = 0.018). Cs4 also improved the quality of life (physical component MD, 7.0; 95% CI, 4.2–9.8; P < 0.001; mental component MD, 6.8; 95% CI, 2.9–10.7; P < 0.001). No severe adverse events were reported. Cs4 may be a beneficial treatment for patients with long COVID symptoms. |
| format | Article |
| id | doaj-art-60451669eb0a4dda96bb45b5ab816e9c |
| institution | Matheson Library |
| issn | 2737-7946 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | Acta Materia Medica |
| spelling | doaj-art-60451669eb0a4dda96bb45b5ab816e9c2025-06-28T16:00:12ZengCompuscript LtdActa Materia Medica2737-79462025-01-014225026110.15212/AMM-2024-0089Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong KongYuanyuan ChenGuang ChenCheng ZhangGuoyi TangYautuen ChanNing WangYibin FengWe assessed Cordyceps sinensis mycelium culture extract (Cs4) for alleviating long COVID symptoms. In this randomized trial 110 participants were assigned to receive Cs4 (55 participants) or were waitlisted (55 participants) for 12 weeks. The primary outcome was the change in long COVID symptom severity at 12 weeks, as measured by the modified COVID-19 Yorkshire Rehabilitation Scale. The secondary outcomes included changes in the Brief Fatigue Inventory Form, Insomnia Severity Index, Hospital Anxiety and Depression Scale, St. George’s Respiratory Questionnaire, and the Short Form 12 health survey at 12 weeks. Participants receiving Cs4 showed improvement in long COVID symptoms compared to the waitlist control group (MD, −10.1; 95% CI, −14.1 to −6.1; P < 0.001) at 12 weeks. Cs4 recipients also experienced improvement in fatigue (MD, −8.1; 95% CI, −14.2 to −2.0; P = 0.011), insomnia (MD, −2.9; 95% CI, −4.6 to −1.2; P = 0.001), and respiratory symptoms (MD, −6.3; 95% CI, −11.4 to −1.2; P = 0.018). Cs4 also improved the quality of life (physical component MD, 7.0; 95% CI, 4.2–9.8; P < 0.001; mental component MD, 6.8; 95% CI, 2.9–10.7; P < 0.001). No severe adverse events were reported. Cs4 may be a beneficial treatment for patients with long COVID symptoms.https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0089 |
| spellingShingle | Yuanyuan Chen Guang Chen Cheng Zhang Guoyi Tang Yautuen Chan Ning Wang Yibin Feng Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong Acta Materia Medica |
| title | Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong |
| title_full | Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong |
| title_fullStr | Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong |
| title_full_unstemmed | Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong |
| title_short | Randomized, waitlist-controlled trial of Cordyceps sinensis mycelium culture extract (Cs4) for long COVID patients in Hong Kong |
| title_sort | randomized waitlist controlled trial of cordyceps sinensis mycelium culture extract cs4 for long covid patients in hong kong |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0089 |
| work_keys_str_mv | AT yuanyuanchen randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong AT guangchen randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong AT chengzhang randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong AT guoyitang randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong AT yautuenchan randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong AT ningwang randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong AT yibinfeng randomizedwaitlistcontrolledtrialofcordycepssinensismyceliumcultureextractcs4forlongcovidpatientsinhongkong |